Johnson & Johnson: Why I See Downside Ahead
Summarize this article with:
ALLKA Research3.35K FollowersFollow5ShareSavePlay(10min)Comment(1)SummaryJohnson & Johnson only slightly raised its 2026 financial guidance.So JNJ expects its operational sales to be between $99.7 billion and $100.7 billion, up from $99.5 billion to $100.5 billion.In my view, this is due to the sharp decline in demand for Stelara, JNJ's former “cash cow” in the immunology franchise.Moreover, JNJ's acquisition of Intra-Cellular Therapies for $14.6 billion doesn't meet my expectations, as Caplyta sales grew by only 8.4% quarter-on-quarter to $270 million.Further in this article, you'll learn about additional reasons why I believe Johnson & Johnson's risk/reward profile is still unattractive. Margaryta Basarab/iStock via Getty Images So, since my last article, “Johnson & Johnson: Strong Run May Be Ending,” which, by the way, caused an extremely negative reaction from you, Johnson & Johnson (JNJ), aka J&J, stockThis article was written byALLKA Research3.35K FollowersFollowWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Research thrives on simplifying investment strategies, ensuring accessibility for both seasoned investors and those just starting.Driven by an unwavering passion for empowering others financially, Allka Research seeks to share its wealth of knowledge through Seeking Alpha. Its mission is to contribute thought-provoking analyses and informed perspectives to the Seeking Alpha community. With a desire to demystify the intricacies of investing, Allka Research aims to inspire confidence in its readers, fostering a community of informed investors who can navigate the markets with intelligence and understanding.
Join Allka Research on this exciting journey of discovery and wealth creation as it continues to unravel the secrets of the financial world on Seeking Alpha.Analyst’s Disclosure: I/we have a beneficial long position in the shares of LEGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.